<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="for Cell Therapy and Immunology, [4], [5], grid.452463.2German Centre for" exact="Infection" post="Research (DZIF), [6], grid.448878.f0000 0001 2288 8774Martsinovsky Institute of"/>
 <result pre="introduced to Brazil in 2014–2015, associated with a rise in" exact="congenital" post="malformations. Unlike the genetically related dengue virus (DENV), ZIKV"/>
 <result pre="(DENV), ZIKV constitutes only one serotype. Although assumed that ZIKV" exact="infection" post="may engender lifelong immunity, the long-term kinetics of ZIKV"/>
 <result pre="response in 144 individuals from 3 different subpopulations: HIV patients," exact="tuberculosis" post="patients and healthy individuals first tested in 2016 and"/>
 <result pre="may fail to account a considerable proportion of past ZIKV" exact="infections" post="in flavivirus endemic countries. In addition, ZIKV immunity might"/>
 <result pre="ZIKV represents only a single serotype to which both the" exact="African" post="and the Asian lineages of ZIKV belong [1, 2]."/>
 <result pre="IgM and IgG antibodies, since viremia is usually low and" exact="transient" post="[4]. ZIKV serologic diagnosis is mostly based on antibodies"/>
 <result pre="ZIKV serologic diagnosis is mostly based on antibodies against two" exact="viral" post="proteins, envelope and NS1 [5]. The envelope protein has"/>
 <result pre="is a non-structural glycoprotein that plays a putative role in" exact="viral" post="replication, and when secreted modulates viral immune invasion and"/>
 <result pre="a putative role in viral replication, and when secreted modulates" exact="viral" post="immune invasion and pathogenesis [7]. The NS1 of flaviviruses"/>
 <result pre="in 2015 causing the biggest outbreak to date [10–12]. The" exact="limited" post="serologic surveys that are available found a high-level population"/>
 <result pre="United Nations Population Division estimates). In Brazil, as other Latin" exact="American" post="countries, cocirculation of other flaviviruses such as DENV, Yellow"/>
 <result pre="Latin American countries, cocirculation of other flaviviruses such as DENV," exact="Yellow fever" post="virus, Bussuquara, Cacipacoré, Ilhéus, Rocio and Saint Louis encephalitis"/>
 <result pre="as DENV, Yellow fever virus, Bussuquara, Cacipacoré, Ilhéus, Rocio and" exact="Saint Louis encephalitis" post="virus might elicit unique flaviviral antibody responses that impact"/>
 <result pre="Yellow fever virus, Bussuquara, Cacipacoré, Ilhéus, Rocio and Saint Louis" exact="encephalitis" post="virus might elicit unique flaviviral antibody responses that impact"/>
 <result pre="the metropolitan region of Salvador, Brazil. Results and discussion A" exact="total" post="of 144 samples were taken from individuals on 2"/>
 <result pre="ZIKV epidemic [5]. Samples belong to three different subpopulations: immunologically" exact="stable" post="HIV-positive patients and healthy individuals from the UHPES and"/>
 <result pre="epidemic [5]. Samples belong to three different subpopulations: immunologically stable" exact="HIV-positive" post="patients and healthy individuals from the UHPES and treated"/>
 <result pre="HIV-positive patients and healthy individuals from the UHPES and treated" exact="tuberculosis" post="patients from the José Silveira Foundation-Brazilian Institute for Investigation"/>
 <result pre="samples were obtained from 28 patients on treatment for active" exact="pulmonary tuberculosis;" post="93 immunologically stable HIV-positive patients under antiretroviral therapy; and"/>
 <result pre="28 patients on treatment for active pulmonary tuberculosis; 93 immunologically" exact="stable" post="HIV-positive patients under antiretroviral therapy; and 23 healthy individuals."/>
 <result pre="patients on treatment for active pulmonary tuberculosis; 93 immunologically stable" exact="HIV-positive" post="patients under antiretroviral therapy; and 23 healthy individuals. Samples"/>
 <result pre="positive by RT-PCR. Although there was no RT-PCR confirmation of" exact="acute" post="ZIKV infection, it is likely that ZIKV antibody responses"/>
 <result pre="the ultra-rapid ZIKV spread in Salvador, northeastern Brazil [5]. Brazil" exact="acquired" post="millions of ZIKV NS1 antigen-based indirect ELISA tests (Euroimmun,"/>
 <result pre="ZIKV in 2017–2018, the majority of which (n = 25; 83.3%) were" exact="HIV-positive" post="individuals (Fig. 1a, c). The level of seroreversion did"/>
 <result pre="c). The level of seroreversion did not differ significantly among" exact="HIV-positive" post="and tuberculosis patients [25 serorevertants (26.9%) versus 5 serorevertants"/>
 <result pre="level of seroreversion did not differ significantly among HIV-positive and" exact="tuberculosis" post="patients [25 serorevertants (26.9%) versus 5 serorevertants (17.8%); Fisher,"/>
 <result pre="less frequently in healthy individuals (1 serorevertant; 4.3%) than in" exact="HIV-positive" post="patients (Fisher, p = 0.03) (Fig. 1c). Fig. 1 a Zika"/>
 <result pre="in 2017–2018 (shown in gray) in the HIV patients (HIV)," exact="tuberculosis" post="patients (TB), healthy individuals (HI) subpopulations and total patients"/>
 <result pre="patients (HIV), tuberculosis patients (TB), healthy individuals (HI) subpopulations and" exact="total" post="patients analyzed for the prospective study. b Comparison between"/>
 <result pre="virus NS1–IgG ratio per subpopulation. Colors as in b. d" exact="Dengue" post="IgG ratios in 2016 between patients that remained positive"/>
 <result pre="seroreversion can be explained by three scenarios. First, seroreversion in" exact="HIV-positive" post="individuals may be associated with lower magnitudes of ZIKV-specific"/>
 <result pre="scenarios. First, seroreversion in HIV-positive individuals may be associated with" exact="lower" post="magnitudes of ZIKV-specific immune responses compared to other subpopulations,"/>
 <result pre="ZIKV-specific immune responses compared to other subpopulations, consistent with generally" exact="lower" post="antibody responses of HIV-positive individuals, e.g., following hepatitis A"/>
 <result pre="to other subpopulations, consistent with generally lower antibody responses of" exact="HIV-positive" post="individuals, e.g., following hepatitis A virus vaccination [19]. However,"/>
 <result pre="with generally lower antibody responses of HIV-positive individuals, e.g., following" exact="hepatitis" post="A virus vaccination [19]. However, the decrease of ELISA"/>
 <result pre="this scenario (Fig. 1c). Second, cross-reactive antibodies elicited by prior" exact="infection" post="with flaviviruses other than ZIKV might have elicited false-positive"/>
 <result pre="ranging from 83.3% 3–6 months to 28.1% 1–2 years after" exact="secondary" post="dengue infections [20]. If this was the case, patients"/>
 <result pre="83.3% 3–6 months to 28.1% 1–2 years after secondary dengue" exact="infections" post="[20]. If this was the case, patients that are"/>
 <result pre="17]. We observed that patients that seroreverted also had significantly" exact="lower" post="PRNT titers (Fig. 1e) and ZIKV NS1-ELISA ratio (Fig."/>
 <result pre="The last explanation for our data could be that the" exact="lower" post="responses observed may be limited to NS1-specific antibodies, which"/>
 <result pre="data could be that the lower responses observed may be" exact="limited" post="to NS1-specific antibodies, which are elicited in infected individuals"/>
 <result pre="NS1-specific antibodies, which are elicited in infected individuals at much" exact="lower" post="magnitude than antibodies against the ZIKV envelope antigen that"/>
 <result pre="ZIKV NS1-specific antibody levels over time was reminiscent of the" exact="complete" post="lack of seroconversion in follow-up samples of two different"/>
 <result pre="follow-up samples of two different cohorts. First, from RT-PCR-confirmed ZIKV" exact="infections" post="in travelers using the same NS1-based serologic test 42"/>
 <result pre="antibodies were readily detected up to three years post-infection in" exact="Brazilian" post="patients [20]. Those data are not at odds with"/>
 <result pre="in northeastern Brazil [5] and individuals frequently have multiple DENV" exact="infections" post="likely boosting NS1-specific immune responses compared to ZIKV, which"/>
 <result pre="in showing loss of ZIKV-specific antibody responses over a comparably" exact="short" post="time span irrespective of the serologic method used for"/>
 <result pre="introduction of the Asian lineage from Latin America potentially causing" exact="congenital" post="malformations, seroprevalence is several orders of magnitude lower than"/>
 <result pre="potentially causing congenital malformations, seroprevalence is several orders of magnitude" exact="lower" post="than the observed for the Pacific islands or Latin"/>
 <result pre="ZIKV antibodies that may both protect from and enhance subsequent" exact="infections" post="[21, 25], and by the growing number of flaviviruses"/>
 <result pre="2.DowdKADeMasoCRPelcRSSpeerSDSmithARYGooLPlattDJMascolaJRGrahamBSMulliganMJDiamondMSLedgerwoodJEPiersonTCBroadly neutralizing activity of Zika virus-immune sera identifies a single" exact="viral" post="serotypeCell Rep20161661485149110.1016/j.celrep.2016.07.04927481466 3.KunoGChangGJFull-length sequencing and genomic characterization of Bagaza,"/>
 <result pre="as a diagnostic biomarkerAntiviral Res201398219220810.1016/j.antiviral.2013.03.00823523765 8.CletonNBGodekeG-JReimerinkJBeersmaMFDoornHRvFrancoLGoeijenbierMJimenez-ClaveroMAJohnsonBWNiedrigMPapaASambriVTamiAVelasco-SalasZIKoopmansMPGReuskenCBEMSpot the difference-development of a" exact="syndrome" post="based protein microarray for specific serological detection of multiple"/>
 <result pre="based protein microarray for specific serological detection of multiple flavivirus" exact="infections" post="in travellersPLoS Neglect Trop Dis201593e000358010.1371/journal.pntd.0003580 9.DickGWKitchenSFHaddowAJZika virus. I. Isolations"/>
 <result pre="14.GallianPCabieARichardPPaturelLCharrelRNPastorinoBLeparc-GoffartITiberghienPde LamballerieXZika virus in asymptomatic blood donors in MartiniqueBlood2017129226326610.1182/blood-2016-09-73798127827826 15.FigueiredoLTMThe" exact="Brazilian" post="flavivirusesMicrobes Infect20002131643164910.1016/S1286-4579(00)01320-411113383 16.FischerCDrostenCDrexlerJFThe difficulties in obtaining reliable Zika virus"/>
 <result pre="17.OliveiraRAde Oliveira-FilhoEFFernandesAIBritoCAMarquesETTenorioMCGilLHPrevious dengue or Zika virus exposure can drive to" exact="infection" post="enhancement or neutralisation of other flavivirusesMem Inst Oswaldo Cruz2019114e19009810.1590/0074-0276019009831411310"/>
 <result pre="Zika virusBull World Health Organ2016941288089210.2471/BLT.16.17595027994281 19.BalmasedaAStettlerKMedialdea-CarreraRColladoDJinXZambranaJVJaconiSCameroniESaborioSRovidaFPercivalleEIjazSDicksSUshiro-LumbIBarzonLSiqueiraPBrownDWGBaldantiFTedderRZambonMde FilippisAMBHarrisECortiDAntibody-based assay discriminates Zika" exact="virus infection" post="from other flavivirusesProc Natl Acad Sci USA2017114318384838910.1073/pnas.170498411428716913 20.NascimentoEJMHuleattJWCordeiroMTCastanhaPMSGeorgeJKGrebeEWelteABrownMBurkeDSMarquesETADevelopment of"/>
 <result pre="virusBull World Health Organ2016941288089210.2471/BLT.16.17595027994281 19.BalmasedaAStettlerKMedialdea-CarreraRColladoDJinXZambranaJVJaconiSCameroniESaborioSRovidaFPercivalleEIjazSDicksSUshiro-LumbIBarzonLSiqueiraPBrownDWGBaldantiFTedderRZambonMde FilippisAMBHarrisECortiDAntibody-based assay discriminates Zika virus" exact="infection" post="from other flavivirusesProc Natl Acad Sci USA2017114318384838910.1073/pnas.170498411428716913 20.NascimentoEJMHuleattJWCordeiroMTCastanhaPMSGeorgeJKGrebeEWelteABrownMBurkeDSMarquesETADevelopment of"/>
 <result pre="and recent dengue virus infectionsJ Virol Methods2018257626810.1016/j.jviromet.2018.04.00929684416 21.PedrosoCFischerCFeldmannMSarnoMLuzEMoreira-SotoACabralRNettoEMBritesCKummererBMDrexlerJFCross-protection of dengue" exact="virus infection" post="against congenital Zika syndrome, Northeastern BrazilEmerg Infect Dis20192581485149310.3201/eid2508.19011331075077 22.HillSCVasconcelosJNetoZJandondoDZe-ZeLAguiarRSXavierJThezeJMirandelaMMicolo"/>
 <result pre="recent dengue virus infectionsJ Virol Methods2018257626810.1016/j.jviromet.2018.04.00929684416 21.PedrosoCFischerCFeldmannMSarnoMLuzEMoreira-SotoACabralRNettoEMBritesCKummererBMDrexlerJFCross-protection of dengue virus" exact="infection" post="against congenital Zika syndrome, Northeastern BrazilEmerg Infect Dis20192581485149310.3201/eid2508.19011331075077 22.HillSCVasconcelosJNetoZJandondoDZe-ZeLAguiarRSXavierJThezeJMirandelaMMicolo"/>
 <result pre="virus infectionsJ Virol Methods2018257626810.1016/j.jviromet.2018.04.00929684416 21.PedrosoCFischerCFeldmannMSarnoMLuzEMoreira-SotoACabralRNettoEMBritesCKummererBMDrexlerJFCross-protection of dengue virus infection against" exact="congenital" post="Zika syndrome, Northeastern BrazilEmerg Infect Dis20192581485149310.3201/eid2508.19011331075077 22.HillSCVasconcelosJNetoZJandondoDZe-ZeLAguiarRSXavierJThezeJMirandelaMMicolo CandidoALVazFSebastiaoCDSWuCHKraemerMUGMeloASchamber-ReisBLFde AzevedoGSTanuriAHigaLMClementeCda"/>
</results>
